Background and aims The efficacy of achieving HBsAg clearance through pegylated
interferon (PEG-IFNα) therapy in patients with chronic hepatitis B (CHB) remains uncertain …

Human hepatitis B virus (HBV) is a small, enveloped DNA virus that causes acute and
chronic hepatitis. Chronic hepatitis B (CHB) is associated with hepatocellular carcinoma …

Background & Aims The optimal therapeutic strategy in nucleoside analogue (NA)
experienced chronic hepatitis B (CHB) using peginterferon is still unclear; hence we …

BACKGROUND Nucleos (t) ide analog (NA) has shown limited effectiveness against
hepatitis B surface antigen (HBsAg) clearance in chronic hepatitis B (CHB) patients. AIM To …

Summary Background & Aims The strategies of adding on or switching to peginterferon
(PEG‐IFN) improved the serological response rates in patients with chronic hepatitis B …

Abstract Background Hepatitis B virus (HBV) has a long history in human infectious
diseases. HBV infection can progress chronically, leading to cancer. After introduction of a …

Background & Aims Functional cure can be sustained in a proportion of patients with chronic
hepatitis B (CHB) who lose hepatitis B surface antigen (HBsAg) after pegylated interferon …

Introduction Hepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis
B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). However, its rate is …

Background: The efficacy of entecavir (ETV) add-on peg-interferon therapy compared with
ETV monotherapy in treatment-naïve hepatitis B virus (HBV) patients remains controversial …

Chronic hepatitis B (CHB) continues to contribute to worldwide morbidity and mortality
significantly. Scientists, clinicians, pharmaceutical companies, and health organizations …